Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00267930 · ClinicalTrials.gov registry record · Phase 2
Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter Recurrence
A Phase 2 study of Atrial Fibrillation, sponsored by Advanz Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 221
- Enrollment target
- 20
- Study locations
NCT00267930: Completed Phase 2 study of Atrial Fibrillation, sponsored by Advanz Pharma.
NCT00267930 is a Phase 2 study of Atrial Fibrillation that has completed, run by Advanz Pharma. The registered enrollment target is 221 participants, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00267930, a Phase 2 study of Atrial Fibrillation, has completed, sponsored by Advanz Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 221 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is designed to evaluate the safety, tolerability and preliminary efficacy of vernakalant (oral) in subjects with sustained atrial fibrillation of greater than 72 hours and less than 6 months duration
Conditions Studied
Interventions
- DRUG Placebo comparator
- DRUG Vernakalant (oral)
Study Locations (20)
Other
- Aalborg Sygehus Syd - Aalborg
- Aarhus Sygehus Kardiologisk Afd. A - Aarhus
- Bispebjerg Hospital - Copenhagen
- Kardiologisk/endokrinologisk afd. E Frederiksberg Hospital - Frederiksberg
- KAS Gentofte Kardiologisk Afdeling - Hellerup
- KAS Herlev - Herlev
- Sygehus Vendsyssel Hjorring - Hjørring
- Medicinsk Afdeling Kolding Sygehus - Kolding
- Roskilde Amts Sygehus Koge - Køge
- Reinier de Graaf Gasthuis - Delft
- Catharina Ziekenhuis - Eindhoven
- Medisch Spectrum Twente - Enschede
- University Medical Center Groningen (UMCG) - Groningen
- Trial sectie Cardiologie - Heerlen
Alabama
- The Heart Center, P.C. - Huntsville
California
- Cardiovascular Consultants Medical Group, Inc. - Walnut Creek
Pennsylvania
- Penn State Heart & Vascular Institute - Hershey
Wisconsin
- Marshfield Clinic - Marshfield
Alberta
- Foothills Hospital - Calgary
Quebec
- Centre Hospitalier de l'Université de Montréal (CHUM) Hôtel Dieu - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 221 participants |
| Start Date | 2005-12 |
| Est. Completion | 2006-08 |
| Phase | Phase 2 |
What the finished NCT00267930 record still lists
NCT00267930 is an interventional study that assigns participants to a tested intervention. The registered 221 participants enrollment target is mid-sized for trials with a published cap, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 2 interventions - of which Placebo comparator is the first listed.
NCT00267930 names 20 study sites across 7 states, led by Other, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT00267930 about?
NCT00267930 is a clinical study titled "Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter Recurrence". This study is designed to evaluate the safety, tolerability and preliminary efficacy of vernakalant (oral) in subjects with sustained atrial fibrillation of greater than 72 hours and less than 6 months duration
What is the current status of trial NCT00267930?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 221 participants. The study started on 2005-12. Estimated completion is 2006-08.
What conditions does trial NCT00267930 study?
This clinical trial studies the following conditions: Atrial Fibrillation.
What interventions are being tested in trial NCT00267930?
The interventions under investigation include: Placebo comparator (DRUG), Vernakalant (oral) (DRUG).
Who is sponsoring clinical trial NCT00267930?
This trial is sponsored by Advanz Pharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00267930 being conducted?
This trial has 20 study locations across Alabama, California, Pennsylvania, Wisconsin, Alberta. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00267930's enrollment target sits among peer trials
221 97th of 202 higher than 106 of 202 other Atrial Fibrillation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer
RECRUITING · Phase 2
-
Chloroquine for Patients With Symptomatic Persistent Atrial Fibrillation: A Prospective Pilot Study
RECRUITING · Phase 2
-
A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation
RECRUITING · Phase 2
-
A Study of Stellate Ganglion Block for Prevention of Atrial Fibrillation
RECRUITING · Phase 2
-
ECG Validation Study
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03170440 · 221 participants · NA
Non-invasive Nerve Stimulation for PTSD and Sleep
- NCT04939610 · 222 participants · Phase 1
A Study of 177Lu-FAP-2286 in Advanced Solid Tumors
- NCT05424783 · 222 participants
MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC)
- NCT05568264 · 222 participants · NA
Effects of a Physical Therapy Intervention on Motor Delay in Infants Admitted to a Neonatal Intensive Care Unit
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia